



(51) International Patent Classification:

C07K 16/18 (2006.01) A61K 35/17 (2025.01)
A61K 39/395 (2006.01) A61K 47/42 (2017.01)
A61K 47/68 (2017.01) C12Q 1/68 (2018.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/058421

(22) International Filing Date:

04 December 2024 (04.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/605,977 04 December 2023 (04.12.2023) US
63/662,231 20 June 2024 (20.06.2024) US
63/686,563 23 August 2024 (23.08.2024) US

(71) Applicant: **NORMUNITY, INC.** [US/US]: One Beacon Street, 15th Floor, Boston, Massachusetts 02108 (US).


(72) Inventors: **ANDREW, David**; c/o Normunity, Inc., One Beacon Street, 15th Floor, Boston, Massachusetts 02108

(US). **COLBERT, Jeff D.**; c/o Normunity, Inc., One Beacon Street, 15th Floor, Boston, Massachusetts 02108 (US). **LAROCHELLE, William**; c/o Normunity, Inc., One Beacon Street, 15th Floor, Boston, Massachusetts 02108 (US). **NEWTH, Rebecca J.**; c/o Normunity, Inc., One Beacon Street, 15th Floor, Boston, Massachusetts 02108 (US). **SHIMKETS, Richard**; c/o Alloy Therapeutics, Inc., 275 Second Avenue, Suite 200, Waltham, Massachusetts 02451 (US). **VINCENT, Thomas**; c/o Alloy Therapeutics, Inc., 275 Second Avenue, Suite 200, Waltham, Massachusetts 02451 (US). **CHANG, Chew Shun**; c/o Alloy Therapeutics, Inc., 275 Second Avenue, Suite 200, Waltham, Massachusetts 02451 (US).

(74) Agent: **LEE, David M.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

(54) Title: ANTI-LY6K ANTIBODIES AND METHODS OF USE



Ab (bivalent)	Sensitivity (pg/mL)	EC50 (ng/mL)
2660 +	6.5	75.56
3520 ⊕	51.8	535.7
3741 ⊠	1	56.77
3035 ◆	136	168.1
3503 ▲	433	63.97
3074 ▼	33	315.4
3743 △	75	111.6
3075 ▽	ND	ND
3082 ◇	3	95.77
3501 ○	5.7	1041
3101 ●	8.6	162.5
R&D* ×	<1	39.52
Abcam* ○	<1	35.73

* Commercial Human LY6K Antibody

FIG. 2

(57) Abstract: The present disclosure provides antibodies and polypeptides that specifically bind to lymphocyte antigen 6 family member K (LY6K). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

[Continued on next page]

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

17 July 2025 (17.07.2025)